Allied Market Research recently published a research report on “Rheumatoid Arthritis Drugs Market by Drug Class, Route of Administration, and Sales Channel: Opportunity Analysis and Industry Forecast, 2020–2027,” the global rheumatoid arthritis drugs market size was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027, registering a CAGR of 2.8% from 2020 to 2027.
Major factors driving the growth of the global rheumatoid arthritis drug market include increasing prevalence of rheumatoid arthritis, increase in demand for rheumatoid arthritis drug therapy, increase in potential clinical pipeline candidates, increasing availability and awareness of safe drugs, increase in approvals. of biosimilar medicines, and the growth of an aging population worldwide.
– The manufacturing of drugs are considered under essential services and thus, the global rheumatoid arthritis drugs market has not been much affected.
– Drugs used for treatment of rheumatoid arthritis like tocilizumab and hydroxychloroquine have also been studied for treatment of the novel corona virus.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭@ https://www.alliedmarketresearch.com/request-sample/3753
By drug class, the market is segmented into disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs, and others. The DMARDs segment dominated the global market in 2019 and is expected to continue this trend during the forecast period.
On the basis of sales channel, the anti-rheumatic drugs market is segmented into prescription-based drugs and over-the-counter (OTC) drugs. The prescription-based medicine segment accounted for the maximum market revenue in 2019 and is expected to continue its dominance over the forecast period due to the increase in the number of specialty hospitals worldwide, as medical conditions require treatment by specialized medical professionals.
Based on region, North America accounted for the largest share of the global arthritis drugs market in 2019 and is expected to remain dominant during the forecast period. This is an increase in research and development activities to develop new drugs and easy availability of arthritis drugs in the region.
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲@ https://www.alliedmarketresearch.com/purchase-enquiry/3753
𝐓𝐨𝐩 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬
The key market players analysed in the global rheumatoid arthritis drugs market report include Amgen Inc., UCB S.A., Eli Lilly and Company, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, and Pfizer Inc. These market players have incorporated several strategies including partnership, expansion, collaboration, joint ventures, and others to brace their stand in the industry.
𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Culture Media Market
𝐀𝐯𝐞𝐧𝐮𝐞 𝐁𝐚𝐬𝐢𝐜 𝐏𝐥𝐚𝐧 | 𝐋𝐢𝐛𝐫𝐚𝐫𝐲 𝐀𝐜𝐜𝐞𝐬𝐬 | 𝟏 𝐘𝐞𝐚𝐫 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 |
Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.
Request for 14 days free trial: https://www.alliedmarketresearch.com/avenue/trial/starter
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.